Ovid Therapeutics (OVID) Net Cash Flow (2016 - 2026)

Ovid Therapeutics has reported Net Cash Flow for 11 years, with the latest figure at $81.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Cash Flow rose 1668.89% year-over-year to $81.0 million; the trailing twelve-month figure through Mar 2026 stood at $73.3 million (up 860.26% YoY), and the FY2025 full-year result was -$12.9 million, down 1649.59% from the prior year.
• Net Cash Flow for Q1 2026 stood at $81.0 million, up from -$7.3 million in the prior quarter.
• The five-year high for Net Cash Flow was $81.0 million in Q1 2026, with the low at -$93.9 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$5.5 million across 5 years, with a median of -$7.3 million in 2025.
• Annual changes were most pronounced in 2022 — Net Cash Flow sank 349.4% — and 2026, when it soared 1668.89%.
• Ovid Therapeutics' Net Cash Flow stood at -$13.4 million in 2022, then slumped by 127.01% to -$30.4 million in 2023, then surged by 137.13% to $11.3 million in 2024, then sank by 164.31% to -$7.3 million in 2025, then soared by 1216.62% to $81.0 million in 2026.
• The last three Net Cash Flow figures came in at $81.0 million (Q1 2026), -$7.3 million (Q4 2025), and -$7.8 million (Q3 2025), per Business Quant data.